Submit Feedback
Recent searches
    Trending searches
    Amgen
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    Amgen's Revenue by Segment

    In fiscal year , Amgen's revenue by segment (products & services) are as follows:


    Learn more about Amgen’s Revenue by Geography

    Check out competitors to Amgen in a side-by-side comparison.

    Explore additional financial metrics for Amgen.

    Continue reading...

    The above chart shows Amgen's revenue percentage share by segment (products and services).

    In fiscal year 2022, Amgen's revenue by segment is as follows:

    • Aranesp generated $1.42B in revenue, representing 7.39% of its total revenue.
    • ENBREL generated $4.12B in revenue, representing 21.41% of its total revenue.
    • Evenity generated $787.00M in revenue, representing 4.09% of its total revenue.
    • Kyprolis generated $1.25B in revenue, representing 6.48% of its total revenue.
    • Neulasta generated $1.13B in revenue, representing 5.86% of its total revenue.
    • Nplate generated $1.31B in revenue, representing 6.8% of its total revenue.
    • Otezla generated $2.29B in revenue, representing 11.9% of its total revenue.
    • Prolia generated $3.63B in revenue, representing 18.87% of its total revenue.
    • Repatha (evolocumab) generated $1.30B in revenue, representing 6.74% of its total revenue.
    • XGEVA generated $2.01B in revenue, representing 10.47% of its total revenue.

    The biggest segment for Amgen is the ENBREL, which represents 21.41% of its total revenue.
    The smallest segment for Amgen is the Evenity, which represents 4.09% of its total revenue.

    The above chart shows Amgen's revenue percentage share by segment (products and services).

    In fiscal year 2023, Amgen's revenue by segment is as follows:

    • Aranesp generated $1.36B in revenue, representing 6.29% of its total revenue.
    • BLINCYTO generated $861.00M in revenue, representing 3.98% of its total revenue.
    • ENBREL generated $3.70B in revenue, representing 17.08% of its total revenue.
    • Evenity generated $1.16B in revenue, representing 5.36% of its total revenue.
    • KRYSTEXXA generated $272.00M in revenue, representing 1.26% of its total revenue.
    • Kyprolis generated $1.40B in revenue, representing 6.48% of its total revenue.
    • Nplate generated $1.48B in revenue, representing 6.82% of its total revenue.
    • Otezla generated $2.19B in revenue, representing 10.11% of its total revenue.
    • Prolia generated $4.05B in revenue, representing 18.7% of its total revenue.
    • Repatha (evolocumab) generated $1.64B in revenue, representing 7.55% of its total revenue.
    • TEPEZZA generated $448.00M in revenue, representing 2.07% of its total revenue.
    • Vectibix generated $984.00M in revenue, representing 4.55% of its total revenue.
    • XGEVA generated $2.11B in revenue, representing 9.76% of its total revenue.

    The biggest segment for Amgen is the Prolia, which represents 18.7% of its total revenue.
    The smallest segment for Amgen is the KRYSTEXXA, which represents 1.26% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2023 2024
    XGEVA 10.47% 9.76% -
    Repatha (evolocumab) 6.74% 7.55% -
    Prolia 18.87% 18.7% -
    Otezla 11.9% 10.11% -
    Nplate 6.8% 6.82% -
    Neulasta 5.86% - -
    Kyprolis 6.48% 6.48% -
    Evenity 4.09% 5.36% -
    ENBREL 21.41% 17.08% -
    Aranesp 7.39% 6.29% -
    Vectibix - 4.55% -
    TEPEZZA - 2.07% -
    KRYSTEXXA - 1.26% -
    BLINCYTO - 3.98% -
    Total Revenue 100% 100% 100%

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Aranesp revenue decreased -100% ($1.36B) from $1.36B (in 2023) to $0.00 (in 2024).
  • BLINCYTO revenue decreased -100% ($861.00M) from $861.00M (in 2023) to $0.00 (in 2024).
  • ENBREL revenue decreased -100% ($3.70B) from $3.70B (in 2023) to $0.00 (in 2024).
  • Evenity revenue decreased -100% ($1.16B) from $1.16B (in 2023) to $0.00 (in 2024).
  • KRYSTEXXA revenue decreased -100% ($272.00M) from $272.00M (in 2023) to $0.00 (in 2024).
  • Kyprolis revenue decreased -100% ($1.40B) from $1.40B (in 2023) to $0.00 (in 2024).
  • Nplate revenue decreased -100% ($1.48B) from $1.48B (in 2023) to $0.00 (in 2024).
  • Otezla revenue decreased -100% ($2.19B) from $2.19B (in 2023) to $0.00 (in 2024).
  • Prolia revenue decreased -100% ($4.05B) from $4.05B (in 2023) to $0.00 (in 2024).
  • Repatha (evolocumab) revenue decreased -100% ($1.64B) from $1.64B (in 2023) to $0.00 (in 2024).
  • TEPEZZA revenue decreased -100% ($448.00M) from $448.00M (in 2023) to $0.00 (in 2024).
  • Vectibix revenue decreased -100% ($984.00M) from $984.00M (in 2023) to $0.00 (in 2024).
  • XGEVA revenue decreased -100% ($2.11B) from $2.11B (in 2023) to $0.00 (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Aranesp $1.42B - $1.36B
    4.15%
    		- -
    BLINCYTO - - $861.00M - - -
    ENBREL $4.12B - $3.70B
    10.20%
    		- -
    Evenity $787.00M - $1.16B
    47.40%
    		- -
    KRYSTEXXA - - $272.00M - - -
    Kyprolis $1.25B - $1.40B
    12.51%
    		- -
    Neulasta $1.13B - - - - -
    Nplate $1.31B - $1.48B
    13.01%
    		- -
    Otezla $2.29B - $2.19B
    4.37%
    		- -
    Prolia $3.63B - $4.05B
    11.58%
    		- -
    Repatha (evolocumab) $1.30B - $1.64B
    26.16%
    		- -
    TEPEZZA - - $448.00M - - -
    Vectibix - - $984.00M - - -
    XGEVA $2.01B - $2.11B
    4.87%
    		- -
    Total Revenue $19.23B - $21.65B
    12.56%
    		-
    100.00%

    Related company

    Related